Anti-tumor activity of rapamycin in glioblastoma
In a clinical trial published this week in PLoS Medicine, Charles Sawyers and colleagues looked at the safety of a drug called rapamycin in a selected group of patients who were undergoingsurgery after recurrence of glioblastoma (a highly malignant tumor of the brain).
In a related research in translation article about the implications of the research, Robert J. Weil, who was not involved in the trial, suggests that the study points the way toward rational design of therapy for stratified groups of patients who share common molecular features and a future that allows cancer researchers and clinicians to reach toward the holy grail of individualized therapy
Citation: Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. (2008) Antitumor activity of rapamycin in patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1): e8
IN YOUR COVERAGE, PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050008
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-01-sawyers.pdf
Memorial Sloan-Kettering Cancer Center
Chairman, Human Oncology and Pathogenesis Program
New York, NY 10021
United States of America
+1 646 888 2594
Related PLoS Medicine research in translation article:
Citation: Weil RJ (2008) Incorporating molecular tools into early-stage clinical trials. PLoS Med 5(1): e21.
IN YOUR COVERAGE, PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO
|Contact: Josh Eveleth|
Public Library of Science